Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment.

Carlin, Aaron F; Clark, Alex E; Garretson, Aaron F; Bray, William; Porrachia, Magali; Santos, AsherLev T; Rana, Tariq M; Chaillon, Antoine; Smith, Davey M

Carlin, Aaron F; Clark, Alex E; Garretson, Aaron F; Bray, William; Porrachia, Magali; Santos, AsherLev T; Rana, Tariq M; Chaillon, Antoine; Smith, Davey M.

Afiliação

Carlin AF; School of Medicine, University of California San Diego, La Jolla, California, USA.
Clark AE; School of Medicine, University of California San Diego, La Jolla, California, USA.
Garretson AF; School of Medicine, University of California San Diego, La Jolla, California, USA.
Bray W; School of Medicine, University of California San Diego, La Jolla, California, USA.
Porrachia M; School of Medicine, University of California San Diego, La Jolla, California, USA.
Santos AT; Department of Public Health, College of Education, Health and Human Services, California State University San Marcos, San Marcos, California, USA.
Rana TM; School of Medicine, University of California San Diego, La Jolla, California, USA.
Chaillon A; School of Medicine, University of California San Diego, La Jolla, California, USA.
Smith DM; School of Medicine, University of California San Diego, La Jolla, California, USA.

Open Forum Infect Dis ; 10(4): ofad154, 2023 Apr.

Article em En | MEDLINE | ID: mdl-37096144

Palavras-chave

COVID-19; Omicron; neutralizing antibodies; nirmatrelvir/ritonavir; reinfection

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google